Search Within

Weinberg Fellows

  1. "Investigational New Drugs"
Formats
  1. Journal Article (5)
Groups
  1. Department of Medicine (5)
  2. Hematology-Oncology Fellows (5)
  3. Solid Tumor Oncology Division (5)
  4. Genitourinary Oncology Service (4)
  5. Gastrointestinal Oncology Service (3)
  6. Body Imaging Service (2)

More Groups

People
  1. Alexander Drilon (2)
  2. Bob Li (2)
  3. Darren Feldman (2)
  4. David Hyman (2)
  5. James Harding (2)
  6. Mario Lacouture (2)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (2)
  4. 2017 (1)
Publications
  1. Investigational New Drugs (5)
Publishers
  1. Springer (5)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies
    Journal Article

    Khalil, D. N.; Prieto González-Albo, I.; Rosen, L.; Lillie, T.; Stacey, A.; Parfitt, L.; Soff, G. A.
    Investigational New Drugs (2023)

    Fulltext@MSK | Save
  • A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors
    Journal Article

    Adra, N.; Vaughn, D. J.; Einhorn, L. H.; Hanna, N. H.; Funt, S. A.; Rosales, M.; Arozullah, A.; Feldman, D. R.
    Investigational New Drugs (2022)

    Fulltext@MSK | Save
  • Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors
    Journal Article

    Ashkar, R.; Feldman, D. R.; Adra, N.; Zaid, M. A.; Funt, S. A.; Althouse, S. K.; Perkins, S. M.; Snow, C. I.; Lazzara, K. M.; Sego, L. M.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • Characterization and management of ERK inhibitor associated dermatologic adverse events: Analysis from a nonrandomized trial of ulixertinib for advanced cancers
    Journal Article

    Wu, J.; Liu, D.; Offin, M.; Lezcano, C.; Torrisi, J. M.; Brownstein, S.; Hyman, D. M.; Gounder, M. M.; Abida, W.; Drilon, A.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save